35265-06-6

Basic information

• Product Name: 2-(cyclopropylamino)ethanol
• Synonyms: 2-(cyclopropylamino)ethanol
• CAS NO: 35265-06-6
• Molecular Formula: C₅H₁₁NO
• Molecular Weight: 101.14694
• Mol File: 35265-06-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 211.5±13.0 °C(Predicted)
• Appearance: /
• Density: 1.02±0.1 g/cm3(Predicted)
• PKA: 14.79±0.10(Predicted)
• CAS DataBase Reference: 2-(cyclopropylamino)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(cyclopropylamino)ethanol(35265-06-6)
• EPA Substance Registry System: 2-(cyclopropylamino)ethanol(35265-06-6)

Safety Data

• Hazardous Substances Data: 35265-06-6(Hazardous Substances Data)

Usage

General Description

2-(cyclopropylamino)ethanol is a chemical compound with the molecular formula C5H11NO. It is a colorless liquid with a faint amine odor, and it is used in various industrial applications. It is also known by its brand name ECT, and it has been studied for its potential use as a pharmaceutical intermediate. The compound is classified as a secondary amine and features a cyclopropyl group, making it particularly interesting for medicinal chemistry research. Its properties and potential uses make it a valuable chemical for various industries and research purposes.

Upstream product

• 722486-66-0 2-(cyclopropylamino)-2-oxoacetic acid ethyl ester 
• 765-30-0 Cyclopropylamine 
• 540-51-2 2-bromoethanol 
• 4755-77-5 Ethyl oxalyl chloride 

Downstream Products

• 918633-67-7 N-cyclopropyl-2-chloroethylamine hydrochloride 
• 1190970-38-7 2-chloro-N-cyclopropyl-N-[2-[2-[2-[(3,3-difluoro-azetidin-1-yl)-methyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-2-oxo-ethoxy]-ethyl]-6-methyl-benzenesulfonic acid amide 
• 1190970-37-6 N-[2-[2-[2-(azetidin-1-yl-methyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-2-oxo-ethoxy]-ethyl]-2-chloro-N-cyclopropyl-6-methyl-benzenesulfonic acid amide 
• 1190971-05-1 tert-butyl 2-(2-(2-chloro-N-cyclopropyl-6-methyl-phenylsulfonylamino)ethoxy)acetate 
• 1186240-93-6 2-(2-(2-chloro-N-cyclopropyl-6-methylphenylsulfonamido)ethoxy)acetic acid 
• 1186240-80-1 N-cyclopropyl-N-(2-(2-(4-(4-cyclopropylpiperazin-1-yl)-4-((1-oxoisoindolin-2-yl)methyl)piperidin-1-yl)-2-oxoethoxy)ethyl)-4-methoxy-2,6-dimethylbenzenesulfonamide 
• 1186240-82-3 N-((1-(2-(2-(N-cyclopropyl-4-methoxy-2,6-dimethylphenylsulfonamido)ethoxy)acetyl)-4-(4-cyclopropylpiperazin-1-yl)piperidin-4-yl)methyl)isonicotinamide 
• 1186240-84-5 N-((1-(2-(2-(N-cyclopropyl-4-methoxy-2,6-dimethylphenylsulfonamido)ethoxy)acetyl)-4-(4-(pyridin-4-yl)piperazin-1-yl)piperidin-4-yl)methyl)acetamide 
• 775287-76-8 [2-[cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulphonyl]amino]ethoxy]acetic acid,1,1-dimethylethyl ester 
• 775287-75-7 N-cyclopropyl-N-(2-hydroxyethyl)-4-methoxy-2,6-dimethylbenzene-sulphonamide 
• 1190971-04-0 2-chloro-N-cyclopropyl-N-(2-hydroxyethyl)-6-methyl-benzenesulfonamide 

Relevant articles and documents

LIPID NANOPARTICLE COMPOSITION

Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination.

Substituted Spiroamine Compounds

Substituted spiroamine compounds corresponding to the formula (I) In which m, n, o, p, Q, r, s, t, R1, R2, R3, R4a, R4b, R5a, R5b, R6a, R6b, R7, R8, R9, R10 and R11 have defined meanings; a process for the preparation of such compounds, pharmaceutical compositions containing such compounds and the use of substituted spiroamines for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin 1 receptor.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide compounds corresponding to formula I processes for the preparation thereof, pharmaceutical compositions containing these compounds, and the use of such substituted sulfonamide compounds in pharmaceutical compositions for the treatment and/or inhibition of pain and other conditions at least partly mediated by the bradykinin 1 receptor